CAR T Cell Therapy Market Size, Share And Top Companies Novartis International AG, Kite Pharma, Juno Therapeutics, Pfizer

Coherent Market Insights has announced the addition of the “CAR-T Cell Therapy Market Size Status and Forecast 2026”, The report classifies the global CAR-T Cell Therapy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global CAR-T Cell Therapy Market Speaker market, analyzes and researches the CAR-T Cell Therapy Market Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Novartis International AG, Kite Pharma, Juno Therapeutics, Pfizer, Bellicum Pharmaceuticals

The Global Car T Cell Therapy Market is expected to be valued at US$ 8.5 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered treatment approach for high success rate in cancer treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products worldwide.

Get The Holistic SAMPLE Of This Business Report: www.coherentmarketinsights.com/insight/request-sample/102

Key takeaways of the market are:

North America is expected to dominate the CAR T cell therapy market throughout the forecast period. The region is expected to account for 58.3% of overall industry share by 2018. Leukemia, lymphoma, and myeloma accounted for 9.4% of 1.6 million newly diagnosed cancer in 2015. Each year, around 55 thousand people die due to leukemia, lymphoma and myeloma in U.S. Emergence of CAR T cell therapy is expected to address the blood cancer concerns. Mortality rate is expected to be drastically lower by 2020 with the adoption of this novel treatment approach.

Europe is expected to be the second largest market for CAR T cell therapy products manufacturers. Although, the region is expected to create lucrative market opportunities, conducting country-specific clinical trials across Europe is expected to be a cumbersome process for companies and is a key challenge for growth prospects in the region.

CD 19 based therapy segment is expected to dominate the global CAR T cell therapy market revenue throughout the forecast period. CD 19 segment is expected to touch a billion dollar mark by 2023. Much of the companies are working on CD 19 to combat leukemia. Other antigens such as CD 20 and CD 22 are also expected to create significant revenue opportunity for treatment of solid tumors.

At present, Novartis International AG and Kite Pharma Inc. are expected to launch their products in 2017. Juno Therapeutics is expected to commercialize its product by 2018. Besides these players, Bellicum Pharmaceutical, Celgene Corporation, and Cellectisare also engaged in R&D process and are focusing on curtailing time-to-market for their product to capitalize the market potential in the following 10 years.

Download The PDF Brochure: www.coherentmarketinsights.com/insight/request-pdf/102

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.